Please login to the form below

Not currently logged in
Email:
Password:

Aptalis

This page shows the latest Aptalis news and features for those working in and with pharma, biotech and healthcare.

HIV prevention pill heads July CHMP recommendations

HIV prevention pill heads July CHMP recommendations

Other positive recommendations were given for Aptalis' Truberzi (eluxadoline) as a treatment for irritable bowel syndrome with diarrhoea, along with two biosimilar versions of Sanofi's clot-busting drug Lovenox (enoxaparin) -

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals during February 2014 Pharma deals during February 2014

    The announcement came just after Forest completed its acquisition of Aptalis last month for $3bn and this month sold a number of products to Hospira's Australian subsidiary Mayne Pharma for

  • Pharma deals during January 2014 Pharma deals during January 2014

    Almost right to the end of the month, the big headline deal was that of Forest with its planned takeover of Aptalis. ... Aptalis itself was only formed in 2011 following the acquisition of Eurand by the Montreal based Axcan Pharma.

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    4, 295. Aptalis/ Forest. Company acquisition. Acquiring sales turnover of $688m. 2, 900.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics